Lineage Cell Therapeutics Inc LCTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LCTX is a good fit for your portfolio.
News
-
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
-
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
-
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
-
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
-
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
-
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
-
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
Trading Information
- Previous Close Price
- $1.14
- Day Range
- $1.13–1.19
- 52-Week Range
- $0.84–1.61
- Bid/Ask
- $1.13 / $1.16
- Market Cap
- $214.93 Mil
- Volume/Avg
- 333,219 / 998,847
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.01
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 75
- Website
- https://www.lineagecell.com
Comparables
Valuation
|
Metric
|
LCTX
|
BLUE
|
FDMT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.15 | 0.49 | 3.69 |
Price/Sales | 22.01 | 4.77 | 49.83 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LCTX
|
BLUE
|
FDMT
|
|---|---|---|---|
Quick Ratio | 2.02 | 1.24 | 15.21 |
Current Ratio | 2.14 | 1.55 | 15.65 |
Interest Coverage | — | — | — |
Quick Ratio
LCTX
BLUE
FDMT
Profitability
|
Metric
|
LCTX
|
BLUE
|
FDMT
|
|---|---|---|---|
Return on Assets (Normalized) | −14.72% | −12.29% | −25.94% |
Return on Equity (Normalized) | −23.50% | −30.63% | −28.64% |
Return on Invested Capital (Normalized) | −24.95% | −15.27% | −31.25% |
Return on Assets
LCTX
BLUE
FDMT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qwrnwxhyk | Mdxg | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jftbyygr | Fkpkkh | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vzhvncfp | Czwvnj | $98.8 Bil | |
MRNA
| Moderna Inc | Ckpbwlrp | Bfp | $38.8 Bil | |
ARGX
| argenx SE ADR | Gbycwlm | Bxfm | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Zkylyfdg | Mlzmz | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rfyqzmbns | Pgysy | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qjbhvghn | Mpghq | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vydbjntkn | Bxblc | $12.4 Bil | |
INCY
| Incyte Corp | Zsxtqfd | Lymlkk | $11.9 Bil |